Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

2

About Drummond Paris

Pharma industry

Drummond Paris Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Drummond Paris News

Drummond Paris named as Chairman of Karus Therapeutics

Jan 14, 2015

Southampton, UK - 12 October 2006 - Innovative biopharmaceutical company Karus Therapeutics has appointed Drummond Paris as Chairman. He is currently President of Kowa Research Europe Ltd and was formerly CEO of Novartis Pharmaceuticals UK. The University of Southampton spin-out was created by in July 2005 by Dr A. Ganesan from the School of Chemistry, cancer scientist Dr Graham Packham and heart biologist Dr Paul Townsend from the School of Medicine. The company plans to develop novel drugs known as histone deacetylase (HDAC) inhibitors to treat cancer and heart disease. There has been intense interest in industry in HDAC inhibitors, which can slow abnormal cell growth, cause controlled cell death and/or correct abnormal cell differentiation in tumours. The next generation products to be developed by Karus are expected to offer patients a potent and less toxic treatment than their predecessors. 'I am delighted to join Karus Therapeutics,' said Mr Paris. 'The company has now developed its science to the stage where it can move forward and achieve a great deal. Karus has tremendous potential in the fields of oncology, dermatology, rheumatoid arthritis and many more conditions. ' Until 2005, Mr Paris was CEO and Country President of Novartis Pharmaceuticals UK. He joined the pharmaceutical industry 28 years ago and, having joined the pre-merged Sandoz in 1977, worked with Novartis for twenty-five years. Karus Therapeutics received £750,000 at its foundation in 2005, a record level of joint seedcorn funding from the IP Group, the early stage technology transfer specialists, and the SULIS fund, a seed fund owned by the Universities of Southampton, Bath and Bristol. It was the 15th company to be spun out of the University of Southampton since 2000, three of which have already listed on the London Stock Exchange. For more information, contact Drummond Paris on 07795 018475. Categories

Drummond Paris Investments

2 Investments

Drummond Paris has made 2 investments. Their latest investment was in Karus Therapeutics as part of their Series A - III on May 5, 2010.

CBI Logo

Drummond Paris Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/5/2010

Series A - III

Karus Therapeutics

$1.06M

No

Esperante, IP Group, and Undisclosed Angel Investors

1

1/8/2009

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/5/2010

1/8/2009

Round

Series A - III

Unattributed VC

Company

Karus Therapeutics

Subscribe to see more

Amount

$1.06M

$99M

New?

No

Subscribe to see more

Co-Investors

Esperante, IP Group, and Undisclosed Angel Investors

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.